Ahmedabad, August 20, 2026: Symbiotec Pharmalab Limited (“Symbiotec Pharmalab” or “The Company”), proposes to open the Bid / Offer Period in relation to its Initial Public Offer of the Equity Shares (“Offer”) on Monday, August 24, 2026.
The Offer comprises a fresh issue of such number of Equity Shares by the Company aggregating up to ₹1,500.00 million (“Fresh Issue”) and offer for sale of up to ₹16,070.00 million (“Offer for Sale”) by certain existing shareholders of the Company (the “Selling Shareholders”) (collectively, the “Total Offer Size”).
The Company proposes to utilise the Net Proceeds towards Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company; and General corporate purposes. (the “Objects of the Offer”)
The Offer for Sale comprises of such number of Equity Shares aggregating up to ₹1,440.00 million by Satwani Holdings LLP (the “Promoter Selling Shareholder”), of such number of Equity Shares aggregating up to ₹9,880.00 million by Rosewood Investments, and of such number of Equity Shares aggregating up to ₹4,750.00 million by India Business Excellence Fund – III (collectively, the “Investor Selling Shareholders”).
The Anchor Investor Bid/Offer Period opens and closes on Friday, August 21, 2026. The Bid/Offer Period will open on Monday, August 24, 2026, for subscription and close on Thursday, August 27, 2026. ( “Bid/Offer Period”).
The Price Band of the Offer has been fixed at ₹938 to ₹988 per Equity Share (the “Price Band”). Bids can be made for a minimum of 15 Equity Shares and in multiples of 15 Equity Shares thereafter (the “Bid Lot”). Discount Of ₹ 90.00 Per Equity Share of Face Value of ₹2 is being offered to Eligible Employees Bidding in the Employee Reservation Portion
This Equity Shares are being offered through the Red Herring Prospectus of the Company dated August 18, 2026 filed with the Registrar of Companies at Madhya Pradesh at Gwalior ( “RoC”).
The Equity Shares to be offered through the Red Herring Prospectus are proposed to be listed on the stock exchanges being BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE” together with BSE, the “Stock Exchanges”). For the purposes of the Offer, BSE Limited is the Designated Stock Exchange. (The “Listing Details”)
JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers to the Offer (“Book Running Lead Managers “or “BRLMs”).
All capitalised terms used herein but not defined shall have the same meaning as ascribed to them in the RHP.
This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”). 40% of the Anchor Investor Portion shall be reserved as under: (i) 33.33% for the domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which allocation will be made to Anchor Investors (“Anchor Investor Allocation Price”) in accordance with the SEBI ICDR Regulations. Any under-subscription in the reserved category specified in clause (ii) above may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the “Net QIB Portion”).
